By combining long-standing expertise with new research solutions, Charles River facilitates drug development in these important disease areas. Our recently validated rodent models provide rapid, cost-effective methods for evaluating the potential efficacy of novel anti-inflammatory agents targeting COPD or asthma conditions.

Successful preclinical studies of stem cell therapies are critical for FDA approval to begin clinical trials, but the current lack of clarity in these guidelines can often hinder preclinical research. Charles River’s highly experienced group of scientists can provide their expertise to support and accelerate the preclinical development of your cellular therapeutics.